Attenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic rats

American Journal of Translational Research

Volumn 2, Issue 2, 2010, Pages 181-189

  Bhatt, Lokesh Kumar ^a   Addepalli, Veeranjaneyulu ^a  

^a Narsee Monjee Institute of Management Studies   (India)

Author keywords

Diabetic retinopathy; Extracellular matrix; Matrix metalloproteinase 2; Matrix metalloproteinase 9

Indexed keywords

ACETYLSALICYLIC ACID; GELATINASE A; GELATINASE B; MINOCYCLINE; STREPTOZOCIN;

AMPLITUDE MODULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B WAVE; BLOOD VESSEL PERMEABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG MECHANISM; DRUG POTENTIATION; ELECTRORETINOGRAM; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GLUCOSE BLOOD LEVEL; HISTOLOGY; LATENT PERIOD; MALE; MONOTHERAPY; NONHUMAN; RAT; RETINA THICKNESS; RISK FACTOR; STREPTOZOCIN DIABETES; VISUAL SYSTEM PARAMETERS; WISTAR RAT; ZYMOGRAPHY;

RATTUS; RATTUS NORVEGICUS;

EID: 77953473424     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Cunha-Vaz JG, Fonseca JR, de Abreu JF, Ruas MA. Detection of early retinal changes in diabetes by vitreous fluorophotometry. Diabetes 1979; 28:16-19.
2. Ishibashi T, Tanaka K, Taniguchi Y. Disruption of blood-retinal barrier in experimental diabetic rats: An E.M. study. Exp Eye Res 1980; 30:401-410.
3. Cogan DG, Toussaint D, Kuwabara T. Retinal vascular pattern. IV. Diabetic retinopathy. Arch Ophthalmol 1961; 66: 366-378.
4. Papachristodoulou D, Heath H, Kang SS. The development of retinopathy in sucrose-fed and streptozotocindiabetic rats. Diabetologia 1976; 12:367-374.
5. Antonetti DABA, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, Kester M, Kimball SR, Krady JK, LaNoue KF, Norbury CC, Quinn PG, Sandirasegarane L, Simpson IA, JDRF Diabetic Retinopathy Center Group (2006) Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006; 55:2401-2411.
6. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW (2002) Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002; 47:S253-262.
7. Zhang J, Wu Y, Jin Y, Ji F, Sinclair SH, Luo Y, Xu G, Lu L, Dai W, Yanoff M, Li W, Xu G-T. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci 2008; 49:732-742.
8. Pradeepa R, Anitha B, Mohan V, Ganesan A, Rema M. Risk factors for diabetic retinopathy in a South Indian Type 2 diabetic population-the Chennai Urban Rural Epidemiology Study (CURES) Eye Study 4. Diabet Med 2008; 25:536-542.
9. Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, Lim SC, Tai ES, Mitchell P. Prevalence and Risk Factors for Diabetic Retinopathy. The Singapore Malay Eye Study. Ophthalmology 2008; 115: 1869-75.
10. Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: Pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord 2008; 9:315-327.
11. Sundling V, Gulbrandsen P, Jervell J, Straand J. Care of vision and ocular health in diabetic members of a national diabetes organization: a cross-sectional study. BMC Health Serv Res 2008; 8:159.
12. Kador PF, Robison WG, Kinoshita JH. The pharmacology of aldose reductase inhibitors. Ann Rev Pharmacol Toxico 125:691-714
13. Ruderman NN, Williamson JR, Brownlee M (1992) Glucose and diabetic vascular disease 1985; FASEB J 6:2905-2914.
14. Greene DA, Lattimer SA, Sima AAF. Sorbitol, phosphoinositide and the sodium-potassium ATPase in the pathogenesis of diabetic complications. New Engl J Med 1987; 316:599-606.
15. Lee TS, Saltsman KA, Ohashi K, King GL. Activation of protein kinase C by elevation of glucose concentration. Proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci USA 1989; 86: 5141-5145.
16. Massova I, Kotra LP, Fridman R, Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification FASEB J 1998; 12, 1075-1095.
17. Yurchenko PD, Schittney JC. Molecular architecture of the basement membrane. FASEB J 1990; 4:1577-1590.
18. Petitclerc E, Boutaud A, Prestayko A, Xu J, Sado Y, Ninomiya Y, Sarras MP Jr, Hudson BG, Brooks PC. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 2000; 275(11):8051-8061.
19. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5 1991; 5: 2145-2154.
20. Matresian LM. The matrix-degrading metalloproteinases. Bioassays 1992; 14:455-463.
21. Hao F, Yu JD. High glucose enhance expression of matrix metalloproteinase-2 in smooth muscle cells. Acta Pharmacol Sin 2003; 24:534-538.
22. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, Harrison DG, Tsao PS. Diabetes mellitus enhances vascular matrix metalloproteinase activity. Role of oxidative stress. Circ Res 2001;88: 1291-1298.
23. Das A, McGuire PG, Eriqat C, et al. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 1999;40:809-813.
24. Das A, McLemore A, Song WS, et al. Retinal neovascularisation is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol 1998;117:498-503.
25. Noda K, Ishida S, Inoue M, et al. Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2003;44:2163-2170.
26. Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 2001;42:789-793.
27. Grant, M. B., Afzal, A., Spoerri, P., Pan, H., Shaw, L. C., & Mames, R. N. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 2004; 13(10), 1275-1293.
28. Qazi Y., Maddula S., Ambati B. K. Mediators of ocular angiogenesis. J. Genet 2009; 88: 495-515.
29. Fletcher EL, Phipps JA, Ward MM, Puthussery T, Wilkinson-Berka JL. Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des 2007; 13:2699-2712.
30. Juen S, Kieselbach GF. Electrophysiological changes in juvenile diabetics without retinopathy. Arch Ophthalmol 1990; 108:372-375.
31. Vadala M, Anastasi M, Lodato G, Cillino S. Electroretinographic oscillatory potentials in insulin-dependent diabetes patients: A long-term follow-up. Acta Ophthalmol Scand 2002; 80:305-309.
32. Layton CJ, Safa R, Osborne NN. Oscillatory potentials and the b-Wave: partial masking and interdependence in dark adaptation and diabetes in the rat. Graefes Arch Clin Exp Ophthalmol 2007; 245:1335-1345.
33. Holopigian K, Greenstein VC, Seiple W, Hood DC, Ritch R. Electrophysiologic assessment of photo-receptor function in patients with primary openangle glaucoma. J Glaucoma 2000; 9:163-168.
34. Zhang Y, Wang Q, Zhang J, Lei X, Xu GT, Ye W. Protection of exendin-4 analogue in early experimental diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2009; 247:699-706.
35. Rundhaug JE. Matrix metalloproteinases, angiogenesis, and cancer. Clin Cancer Res 2003; 9 (2):551-4.
36. Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev 2003; 23(2):117-45.
37. Low Pl. Pathogenesis of Diabetic Neuropathy. In: Joslin EP, Ronald CK (ed) Joshlin's Diabetes Mellitus, 2005; 14th edn. Lippincott, Williams and Wilkins, Philadelphia, pp 841-842.
38. Ito H, Duxbury M, Benoit E, Farivar RS, Gardner-Thorpe J, Zinner MJ, Ashley SW, Whang EE. Fibronectin-induced COX-2 mediates MMP-2 expression and invasiveness of rhabdomyosarcoma. Biochem Biophys Res Commun 2004; 28:594-600.
39. Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD. Matrix metalloproteinases and diabetic vascular complications. Angiology 2005; 56(2):173-89.
40. Giebel SJ, Menicucci G, McGuire PG, Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Laboratory Investigation 2005; 85:597-607.